Roivant empowers a global team of innovators from within and beyond the biopharmaceutical industry.
We tackle the most pressing challenges in healthcare today.
Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.
Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.
Chief Executive Officer
EVP, Roivant Health
Head of People
Jason Imbriglio, PhD
Vice President, Discovery Chemistry
Chief Information Officer
Chief Accounting Officer
Chief Commercial Officer
Matt Maisak, PhD
Chief Operating Officer, Roivant Platforms
James C. Momtazee
Tudor Oprea, MD, PhD
Vice President, Translational Informatics
Chairman of the Board
Chief Financial Officer
Srini Ramanathan, PhD
Chief Development Officer
Mayukh Sukhatme, MD
President & Chief Investment Officer
Iván Cornella-Taracido, PhD
Vice President of Translational Chemical Biology
Frank Torti, MD
Eric Valeur, PhD
Vice President, Head of Drug Discovery
Eric Venker, MD
President & Chief Operating Officer
Huafeng Xu, PhD
Chief Technology Officer
Learn more about our work
Sign up for our latest announcements and upcoming presentations
Advancing medicines that matter
View our broad and differentiated pipeline of investigational drugs.